Ipsen and Day One enter into unique ex-U.S. licensing settlement to commercialize tovorafenib for the most typical childhood mind tumor
Ipsen secures ex-U.S. regulatory and industrial rights to tovorafenib for most typical childhood mind tumor, pediatric low-grade glioma (pLGG), and ...